Last updated: 2026-09-29 23:32:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Profusa, Inc. (PFSA) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2.25, with a market capitalisation of $1.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $3,000.00. This page covers its latest market performance, valuation, price trends and company information.
$1.02M | |
$1.66 | |
$18,000.00 | |
$1.58 | |
$1.69 | |
10.57M | |
2.55M | |
-- | |
$3,000.00 | |
$1.58 | |
-- | |
-- |
Profusa, Inc. (PFSA) is trading at $2.16 in after-hours trading as of 2026-09-29 23:31:00, up 27.51% ($0.46) from the regular-session close of $1.69.
After-hours trading shows how investors are pricing PFSA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Profusa, Inc. (PFSA) moved from $1.94 to $2.25, representing a gain of 15.77% ($0.31).
The stock traded between $1.65 and $4.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 12.66 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
PFSA is currently trading at $2.25, placing it 0.0% of the way from its 52-week low of $1.58 to its 52-week high of $3,000.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profusa, Inc. (PFSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.